Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

ClinicalTrials.gov ID: NCT00798707

Public ClinicalTrials.gov record NCT00798707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (25 and 50 mg/Day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Study identification

NCT ID
NCT00798707
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
709 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2008
Primary completion
Mar 31, 2010
Completion
Mar 31, 2010
Last update posted
Jun 9, 2011

2008 – 2010

United States locations

U.S. sites
19
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Pfizer Investigational Site Arcadia California 91007
Pfizer Investigational Site Beverly Hills California 90210
Pfizer Investigational Site Cerritos California 90703
Pfizer Investigational Site Garden Grove California 92845
Pfizer Investigational Site Los Alamitos California 90720
Pfizer Investigational Site St. Petersburg Florida 33702
Pfizer Investigational Site Atlanta Georgia 30328
Pfizer Investigational Site Smyrna Georgia 30080
Pfizer Investigational Site Libertyville Illinois 60048
Pfizer Investigational Site Dayton Ohio 45408
Pfizer Investigational Site East Providence Rhode Island 02914
Pfizer Investigational Site Columbia South Carolina 29201
Pfizer Investigational Site Memphis Tennessee 38117
Pfizer Investigational Site Dallas Texas 75230
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Salt Lake City Utah 84107
Pfizer Investigational Site Kirkland Washington 98033
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Brown Deer Wisconsin 53223

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00798707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2011 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00798707 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →